On September 21, 2024, Chris Palmer, M.D., presented at a BSI Medical Society event in Boston. Dr. Palmer discussed the rising prevalence of mental illness and the limited success of current treatments like medications and therapy, which often fail to address the underlying causes. He proposes a new approach: considering mental disorders as metabolic disorders that impact the brain, rather than attributing them solely to neurotransmitter imbalances or trauma. By focusing on metabolic health, he suggests we might unify various risk factors—like genetics, stress, and environmental influences—under a single framework that connects physical and mental health.

Palmer argues that mitochondrial dysfunction in the brain could be the root cause of many mental health issues, explaining why mental illnesses often co-occur with metabolic disorders such as obesity and diabetes. People with mental disorders are more likely to develop metabolic diseases, and vice versa.

Palmer also highlights the potential of metabolic treatments, like the ketogenic diet, to improve mental health outcomes by enhancing mitochondrial function. He points out that while some psychiatric medications positively affect mitochondria, others may harm metabolic health, leading to side effects that worsen long-term outcomes.

Dr. Palmer’s ongoing research aims to validate the metabolic theory of mental illness, with the hope of developing more effective, lifestyle-focussed interventions—such as diet, exercise, and supplements—alongside traditional mental health treatments.

This talk was given during the BSI Medical Society Evolution of the Revolution Tour.

Learn more about our Medical Society here.


More From the Series

Professor Thomas Seyfried presents at a BSI Medical Society event in Boston. His talk focuses on cancer as a mitochondrial metabolic disease rather than a genetic one.

Also from the Boston event, Emily Kaplan addresses the systemic failures in modern science and healthcare.

Let's start with the truth!

Support the Broken Science Initiative.
Subscribe today →

Leave A Comment

recent posts

    If you're seeing this page, you are not currently logged into a profile with access to Affiliate Owners / Medical.

    At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.

    The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.

    An abbreviated version of this discussion is available here, for free.

    At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.

    Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.

    The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.

    An abbreviated version of this discussion is available here, for free.

    MetFix and BSI Members can view the full 54-minute video.